Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Atrial fibrillation (AF) management increasingly favors restoring and maintaining normal sinus rhythm.
• Antiarrhythmic therapy is crucial for preventing AF recurrence after rhythm conversion.
• Balancing efficacy and safety, particularly proarrhythmia risk, is vital in antiarrhythmic drug selection.

Purpose of the Study:

• To review current strategies for antiarrhythmic therapy in atrial fibrillation.
• To highlight the role of Class III antiarrhythmic agents in patients with structural heart disease.
• To emphasize the shift towards evidence-based, individualized benefit-risk evaluations in AF pharmacotherapy.

Main Methods:

• Review of current clinical opinion and research on atrial fibrillation management.
• Analysis of the efficacy and safety profiles of various antiarrhythmic drug classes.
• Focus on Class III agents (amiodarone, sotalol, dofetilide, ibutilide, azimilide) for AF with structural heart disease.

Main Results:

• Flecainide and propafenone are effective for AF without significant cardiac disease.
• Class III agents show promise for AF patients with structural heart disease, with amiodarone and sotalol being of primary interest.
• These agents demonstrate efficacy in maintaining sinus rhythm with a low incidence of proarrhythmia when used appropriately.

Conclusions:

• Pharmacologic therapy for atrial fibrillation is evolving towards individualized benefit-risk assessments.
• Class III antiarrhythmic agents are increasingly important for managing AF, especially in patients with structural heart disease.
• Future AF treatment will likely involve drugs prolonging atrial repolarization, guided by controlled clinical trials.